amantadine has been researched along with perphenazine in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (21.43) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (64.29) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Spoerlein, MT; VanderWende, C | 1 |
| Cates, LA; Cramer, MB; Gallio, RL | 1 |
| Hitomi, M; Mori, J; Oashi, T; Sato, Y | 1 |
| Petroianu, GA; Stegmeier-Petroianu, A | 1 |
1 review(s) available for amantadine and perphenazine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
13 other study(ies) available for amantadine and perphenazine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Role of dopaminergic receptors in morphine analgesia and tolerance.
Topics: Amantadine; Analgesia; Animals; Apomorphine; Dibenzothiazepines; Dopamine; Drug Synergism; Drug Tolerance; Male; Mice; Mice, Inbred Strains; Morphine; Perphenazine; Phenoxybenzamine; Receptors, Adrenergic; Serine; Spiro Compounds | 1973 |
Phosphorus--nitrogen compounds. XV. N-1-adamantylphosphoramidic dichloride and dimethyl and diphenyl N-1-adamantylphosphoramidate.
Topics: Amantadine; Animals; Antiparkinson Agents; Atropine; Guinea Pigs; Leukemia L1210; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred Strains; Motor Activity; Organophosphorus Compounds; Oxotremorine; Perphenazine; Spectrophotometry, Infrared; Tremorine | 1973 |
[Pharmacological study of amantadine, a new antiparkinson drug].
Topics: Amantadine; Amines; Animals; Antiparkinson Agents; Avoidance Learning; Brain; Catatonia; Dopamine; Drug Synergism; Haloperidol; Humans; Iris; Male; Methamphetamine; Mice; Movement; Oxotremorine; Perphenazine; Rats; Synaptosomes; Tremor; Tremorine | 1974 |
Hiccups and dopamine.
Topics: Amantadine; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Dopamine Antagonists; Hiccup; Humans; Parkinson Disease; Perphenazine; Pramipexole | 2008 |